newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

  • Sales of CyPath Lung increased more than 100% in Q3 2026 compared to Q3 2025.
  • The number of physicians ordering the test rose by 89% in Q3 2026 versus the same period in 2025.
  • Physicians who ordered CyPath Lung through Q3 2025 increased their usage volume by 48% year-over-year.
  • Testing volume reached over 1620 in Q3 2026, compared to 775 in Q3 2025.
  • Growth in utilization occurred across pulmonology, oncology, lung nodule clinics, 82; community medical centers.
  • bioAffinity Technologies entered a new distribution agreement with Veteran-Owned AvMEDICAL to broaden reach within the government healthcare system.
  • The test uses flow cytometry & AI to analyze sputum for cell populations indicating malignancy.
  • Clinical trial data showed 92% sensitivity, 87% specificity, 88% accuracy, 82; 99% negative predictive value for nodules under 20 millimeters.
  • CyPath Lung is marketed as a Laboratory Developed Test (LDT) overseen by CLIA regulations 82; it is not a sole diagnostic tool.